Portage Biotech Inc


Portage Biotech Inc

Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.68
  • Today's Change0.079 / 3.05%
  • Shares traded37.98k
  • 1 Year change-61.39%
  • Beta--
Data delayed at least 15 minutes, as of Mar 24 2023 19:49 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Portage Biotech Inc. is a Canada-based clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with evasive cancers. The Company’s access to technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Company’s portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Its portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

  • Revenue in USD (TTM)0.00
  • Net income in USD-17.48m
  • Incorporated--
  • Employees6.00
  • Location
    Portage Biotech Inc47 Avenue Rd Suite 200TORONTO M5R 2G3CanadaCAN
  • Phone+1 (416) 929-1806
  • Fax+1 (416) 929-6612
  • Websitehttps://portagebiotech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PRTG:NAQ since
iOx Therapeutics LtdDeal completed20 Jul 202220 Jul 2022Deal completed-71.44%35.07m
Data delayed at least 15 minutes, as of Mar 24 2023 19:49 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Eiger Biopharmaceuticals Inc13.48m-96.78m42.80m56.00--0.7723--3.17-2.34-2.340.32411.250.10940.67236.24240,785.70-78.51-56.95-101.06-67.8386.38---717.71-1,242.444.57-30.410.4174--11.05---185.33--50.52--
Synlogic Inc1.67m-64.54m42.98m84.00--0.4266--25.80-0.8954-0.89540.02311.430.0105--1.3319,833.33-40.49-38.80-43.52-41.38-----3,873.95-2,739.74----0.0002--221.8331.62-2.35---18.09--
Genprex Inc0.00-22.66m43.66m17.00--1.47-----0.473-0.4730.000.57240.00----0.00-59.41-94.20-62.37-98.73------------0.00-------9.21---4.15--
Taysha Gene Therapies Inc0.00-160.68m43.70m178.00--2.59-----4.12-
LifeVantage Corp206.38m-723.00k43.75m259.00--1.3715.950.212-0.0699-0.069916.492.512.952.2785.56796,841.70-1.0313.96-1.5323.7980.2882.82-0.35033.871.0328.390.00---6.280.6796-75.8014.187.72--
Hookipa Pharma Inc14.25m-64.92m44.08m156.00--0.4299--3.09-1.29-1.290.26691.870.0961--2.1291,339.74-43.79-37.65-55.67-44.36-----455.58-339.50----0.0239---22.76--14.21--31.07--
Know Labs Inc8.69k-18.54m44.35m19.00--6.33--5,103.16-0.4356-0.43560.00020.14530.0007----543.13-144.85-234.54-821.31-------213,319.80-659.70---4.080.2435-----2.2120.86------
Portage Biotech Inc0.00-17.48m44.37m6.00--0.2627-----1.17-
Beyondspring Inc1.35m-64.18m44.41m103.00--1.66--32.87-1.64-1.640.03460.68550.0136----13,116.50-68.66-130.61-81.89-169.71-----5,048.71-21,307.90----0.0561--650.56---5.26--113.57--
Movano Inc0.00-28.71m44.43m27.00--3.02-----0.8746-0.87460.000.43760.00----0.00-94.08---106.58--------------0.00-------10.56------
NextCure Inc0.00-74.73m44.72m99.00--0.2669-----2.69-2.690.006.030.00----0.00-35.04-20.55-36.38-21.45-------825.97----0.00-------7.70---24.55--
Praxis Precision Medicines Inc0.00-214.03m44.73m109.00--0.554-----4.66-4.660.001.540.00----0.00-104.95---127.74--------------0.00-------28.11------
Aquestive Therapeutics Inc47.68m-54.41m44.96m157.00------0.9429-1.14-1.140.9793-2.160.81043.955.67---92.48-90.80-194.23-141.7659.3466.46-114.11-116.620.8596-3.41-----6.20-6.5522.87------
Psycheceutical Bioscience Inc1.16m-149.52k46.21m28.00--0.5295--39.94-0.1157-0.11570.89530.33990.630898.602.3441,318.93-8.15-19.61-29.82-55.3660.5039.98-12.92-43.930.959--0.0906---30.5283.3743.79------
Data as of Mar 24 2023. Currency figures normalised to Portage Biotech Inc's reporting currency: US Dollar USD

Institutional shareholders

0.92%Per cent of shares held by top holders
HolderShares% Held
MAI Capital Management LLCas of 31 Dec 202257.51k0.34%
BlackRock Fund Advisorsas of 31 Dec 202227.82k0.16%
Dimensional Fund Advisors LPas of 31 Dec 202218.33k0.11%
Sigma Planning Corp.as of 31 Dec 202211.86k0.07%
Ergoteles LLCas of 31 Dec 202210.85k0.06%
Advisor Partners II LLCas of 31 Dec 202210.10k0.06%
Pathstone Family Office LLCas of 31 Dec 202210.10k0.06%
Barclays Bank Plc (Private Banking)as of 31 Dec 20225.66k0.03%
Tower Research Capital LLCas of 31 Dec 20222.84k0.02%
Morgan Stanley & Co. LLCas of 31 Dec 20222.67k0.02%
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.